M. E. Mccann

发表

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

G. Scapin, N. Thornberry, R. S. Roy, 2005, Journal of medicinal chemistry.

A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.

Margaret S. Wu, J. Berger, T. Doebber, 2008, European journal of pharmacology.

Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonists.

M. Forrest, M. E. Mccann, J. Tata, 2007, Journal of pharmacological and toxicological methods.

Selective PPARgamma modulators with improved pharmacological profiles.

Margaret S. Wu, J. Berger, D. Moller, 2005, Bioorganic & medicinal chemistry letters.

Discovery of novel, potent, selective, and orally active human glucagon receptor antagonists containing a pyrazole core.

V. Ding, S. Qureshi, K. Chapman, 2011, Bioorganic & medicinal chemistry letters.

Madin-Darby Canine Kidney II Cells: A Pharmacologically Validated System for NPC1L1-Mediated Cholesterol Uptake

F. Ujjainwalla, M. Braun, Y. S. Tang, 2008, Molecular Pharmacology.

Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.

Margaret S. Wu, J. Berger, Gaochao Zhou, 2011, Journal of medicinal chemistry.

Effect of intravenous infusion of omega-3 and omega-6 lipid emulsions on equine monocyte fatty acid composition and inflammatory mediator production in vitro.

M. Barton, J. Moore, M. E. Mccann, 2000, Shock.

Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.

J. Berger, T. Doebber, M. E. Mccann, 2009, Journal of medicinal chemistry.

Selective PPARγ modulators with improved pharmacological profiles

Margaret S. Wu, J. Berger, D. Moller, 2005 .

Spiroimidazolidinone NPC1L1 inhibitors. 1: Discovery by 3D-similarity-based virtual screening.

Daniel R McMasters, V. Maiorov, J. Lisnock, 2009, Bioorganic & medicinal chemistry letters.

Conservative management of femoral diaphyseal fractures in four foals.

M. E. Mccann, R. Hunt, 1993, The Cornell veterinarian.

In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis.

C. Brideau, G. Hickey, M. E. Mccann, 2004, American journal of veterinary research.

Effects of acetylpromazine, xylazine, and vertical load on digital arterial blood flow in horses.

M. E. Mccann, R. Hunt, C. Brandon, 1994, American journal of veterinary research.

In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in cats with lipopolysaccharide-induced pyrexia.

C. Brideau, G. Hickey, M. E. Mccann, 2005, American journal of veterinary research.

Extracellular loop C of NPC1L1 is important for binding to ezetimibe

W. Bildl, U. Schulte, M. E. Mccann, 2008, Proceedings of the National Academy of Sciences.

Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma an

Margaret S. Wu, Harold B Wood, Yejun Tan, 2009, Journal of medicinal chemistry.

Spiroimidazolidinone NPC1L1 inhibitors. Part 2: structure-activity studies and in vivo efficacy.

Daniel R. McMasters, J. Lisnock, R. DeVita, 2010, Bioorganic & medicinal chemistry letters.